Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical
Portfolio Pulse from Benzinga Insights
Ultragenyx Pharmaceutical (NASDAQ:RARE) received mixed analyst ratings with an average 12-month price target of $92.75, marking a 20.14% increase from the previous target. The company's financial health shows strong revenue growth and efficient cost management but faces challenges in ROE and ROA. Its market capitalization is below industry benchmarks, indicating potential growth constraints.

March 18, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx Pharmaceutical received mixed analyst ratings, with an updated average 12-month price target of $92.75, indicating a potential upside. The company's strong revenue growth and efficient cost management are positive, but challenges in ROE and ROA could concern investors.
The mixed analyst ratings with a significant increase in the average price target suggest optimism about Ultragenyx Pharmaceutical's future performance. The strong revenue growth is a positive indicator, but the challenges in ROE and ROA may temper investor enthusiasm. The overall impact is likely positive in the short term due to the raised price targets and revenue growth.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100